Abstract
Renal cell cancer (RCC) continues to be among the most lethal malignancies in the USA. Introduction of anti-vascular epidermal growth factor receptor tyrosine kinase inhibitors over a decade ago resulted in improvement in disease outcomes, but further development of new therapies largely stagnated for many years. More recently, a better understanding of disease biology and treatment-resistance patterns has led to a second renaissance in drug development, with the anti-programmed cell death protein 1 immune checkpoint inhibitor, nivolumab, paving the way for additional therapies entering clinical trial testing in the treatment of RCC.
Original language | English |
---|---|
Pages (from-to) | 287-298 |
Number of pages | 12 |
Journal | Therapeutic Advances in Medical Oncology |
Volume | 9 |
Issue number | 4 |
DOIs | |
State | Published - 1 Apr 2017 |
Keywords
- clear cell
- immunotherapy
- renal cell carcinoma
- targeted therapies
- vascular epidermal growth factor